|
11 |
Effectiveness and Safety Data in Rheumatoid Arthritis Patients after Switching from Originator Rituximab to Biosimilar Rituximab (CT-P10)
Enthalten in Aktuelle Rheumatologie 01.10.2024
|
|
|
|
12 |
Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials
Enthalten in Clinical and translational oncology 18.9.2024: 1-13
|
|
|
|
13 |
Clinical Utilization of Generic Drugs and Biosimilars for Ulcerative Colitis Treatment: Insights from a Nationwide Database Study in Japan
Enthalten in Inflammatory intestinal diseases Bd. 9, 2024, Nr. 1: 29-39. 11 S.
|
|
|
14 |
Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response — data from the German HS registry HSBest
Kirsten, Natalia. - Würzburg : Universität Würzburg, 2023
|
|
|
|
15 |
In Defense of Disinformation
Enthalten in Journal of homeland security and emergency management Bd. 21, 2023, Nr. 3: 441-466. 26 S.
|
|
|
|
16 |
Evaluating the Impact of Data Exclusivity on the Price of Pharmaceutical Imports
Enthalten in Journal of globalization and development Bd. 14, 2023, Nr. 1: 1-20. 20 S.
|
|
|
|
17 |
Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid® in adult patients with type 2 diabetes mellitus
Enthalten in Journal of endocrinological investigation 26.12.2023: 1-12
|
|
|
|
18 |
Re-exposure with a TNF inhibitor bio-similar was well tolerated and led to sustained control of psoriatic arthritis after allergic reaction to the TNF inhibitor bio-originator
Valor-Méndez, Larissa. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2022
|
|
|
|
19 |
GLODAPv2.2022: the latest version of the global interior ocean biogeochemical data product
Enthalten in Earth system science data Bd. 14, 2022, Nr. 12: 5543-5572. 30 S.
|
|
|
|
20 |
Effectiveness of SB4 transition from originator etanercept in rheumatoid arthritis and axial spondyloarthritis: A subgroup analysis from the BENEFIT study
Enthalten in Rheumatology and immunology research Bd. 3, 2022, Nr. 1: 31-37. 7 S.
|
|
Administration
